PLoS ONE (Jan 2023)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.

  • Jack E Heron,
  • Hamish McManus,
  • Tobias Vickers,
  • Kathleen Ryan,
  • Edwina Wright,
  • Allison Carter,
  • Mark Stoove,
  • Jason Asselin,
  • Andrew Grulich,
  • Basil Donovan,
  • Rebecca Guy,
  • Rick Varma,
  • Marcus Chen,
  • Nathan Ryder,
  • David A Lewis,
  • David J Templeton,
  • Catherine C O'Connor,
  • David M Gracey,
  • ACCESS Collaboration

DOI
https://doi.org/10.1371/journal.pone.0280339
Journal volume & issue
Vol. 18, no. 2
p. e0280339

Abstract

Read online

BackgroundTenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure prophylaxis (PrEP).Methods and findingsData were extracted from 52 sexual health clinics across Australia from 2009-2019. All patients prescribed TDF-containing antiretroviral therapy and PrEP were included. Rates of renal impairment (a fall in eGFR to ConclusionPatients prescribed TDF-based PrEP had lower rates of renal impairment than patients prescribed TDF for HIV infection. In propensity analysis, after matching for some risk factors, rates of renal impairment remained higher amongst patients with HIV.